According to Regencell Bioscience Holdings latest financial reports the cash on hand of RGC is $11.56M, an decrease of -29.56% to 2022. At the end of 2022 company had $16.42M cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $11.56M | -29.56% |
2022 | $16.42M | 27532.00% |
2021 | $59.41K | -84.65% |
2020 | $386.98K | 59.05% |
2019 | $243.31K | - |